(IN BRIEF) A Phase III trial of Tezspire (tezepelumab) by AstraZeneca and Amgen has shown significant benefits for patients ...

A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...

Amgen (AMGN) and AstraZeneca's (AZN) asthma therapy Tezspire hits main goals in the Phase 3 trial for chronic rhinosinusitis ...

Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...

(Alliance News) - AstraZeneca PLC on Friday said it received positive results from a trial of Tezspire as a treatment for chronic rhinosinusitis with nasal polyps.

compared to a placebo in adults with severe chronic rhinosinusitis with nasal polyps, showed a "statistically significant and ...

AstraZeneca (GB:AZN) has released an update. AstraZeneca’s Tezspire has shown promising results in the Phase III WAYPOINT trial, ...

A sinus infection, also known as sinusitis, occurs when the air cavities around your nasal passages become inflamed and ...

Expert says, that by recognising the connection between seasonal changes, allergies, and sinus health, individuals can take ...

showed efficacy in a phase 3 trial in patients with chronic rhinosinusitis with nasal polyps (CRwNP). The WAYPOINT trial ...

Today's health news includes what RFK Jr. can do on vaccines, escaped monkeys, and who know in the Make America Healthy Again ...